Noopept vs Piracetam: Chemistry, Evidence and Legal Status Compared

Piracetam is the original racetam, a GABA derivative licensed as a prescription medicine in the UK and parts of Europe, used in grams. Noopept (omberacetam) is a Russian-developed dipeptide prodrug often grouped with racetams, used in milligrams. The main differences are chemistry, dose, the depth of research and regulatory standing, and neither is an approved drug in the US.¹⁴⁵⁸

Online comparisons often call noopept “1,000 times more potent” than piracetam. That figure refers to the milligram dose, not to a greater effect, and most of the research behind noopept comes from animal studies at a single Russian laboratory.⁵

This page sets out what each compound is, what the limited human trials found, what can go wrong, and where each stands legally in the US, UK, EU and Canada as of September 2026. We do not give dosing or sourcing advice.

At a glance

Property	Noopept (omberacetam)	Piracetam
Chemical class	Dipeptide ester (N-phenylacetyl-L-prolylglycine ethyl ester)	Cyclic GABA derivative (2-oxo-pyrrolidine acetamide)
Origin	Zakusov Institute of Pharmacology, Russia	Marketed worldwide mainly by UCB Pharma
Active form	Metabolite cycloprolylglycine	Piracetam itself
Dose scale in studies	Milligrams	Grams
Human trials	One open-label trial of 31 people on noopept	Many trials; Cochrane reviews inconclusive
Licensed uses	Used clinically in Russia	UK: cortical myoclonus (prescription only); authorised in 20+ EU/EEA states
US status	Unapproved; FDA says not a dietary supplement	Unapproved; FDA says not a dietary supplement
Label accuracy in US tests	Found at up to four times a typical drug dose	Four of five brands contained it, doses varied widely
Key safety notes	Sleep problems, irritability, blood pressure rises reported	Affects platelets; contraindicated in cerebral haemorrhage

What noopept and piracetam are

Piracetam is a cyclic derivative of the neurotransmitter GABA and the parent of the racetam family. A 2005 review described effects on cell membrane fluidity, cholinergic and glutamatergic transmission and blood flow, while noting that high doses are sometimes needed.¹ Its UK prescribing information also describes effects on platelets and red blood cells.⁴

Noopept, also known as omberacetam and originally GVS-111, was developed at the Zakusov Institute of Pharmacology in Moscow based on piracetam’s structure. Chemically it is a dipeptide, not a true racetam. In rodents it crosses into the brain but has a half-life of only minutes; much of its activity is attributed to a metabolite, cycloprolylglycine.⁵

Proposed mechanisms

• Piracetam: modulation of acetylcholine and glutamate signalling, membrane effects and effects on blood cells and microcirculation; no single mechanism is established.¹
• Noopept: rat studies report increased expression of nerve growth factor and BDNF in the hippocampus, and protection against glutamate toxicity in cell cultures.⁷⁵

Almost all the noopept mechanism work comes from one laboratory using non-standard animal models, which limits how far it can be generalised.⁵

What the human studies found

Piracetam

Piracetam has been tested in dementia, stroke, vertigo and other conditions for decades. A Cochrane review of dementia and cognitive impairment trials found more people improved on a global impression scale with piracetam than placebo, but no benefit on any more specific measure, and concluded the published evidence did not support its use.² A Cochrane review of acute ischaemic stroke found no difference in functional outcome or dependence and a non-significant trend towards more early deaths, possibly explained by differences in stroke severity.¹²

There is little good evidence in healthy adults. Most trials enrolled older people with diagnosed conditions, and many were small, short or of crossover design. The Cochrane dementia reviewers noted that the main manufacturer supplied a list of studies, many unpublished, and that first-phase data from crossover trials often could not be extracted.² That is a common pattern with older drugs: a large volume of research that is hard to pool and of uneven quality.

Piracetam’s licensed use in the UK today is narrow: cortical myoclonus, a movement disorder, not memory or concentration.⁴ Being an authorised medicine does not mean it has been shown to enhance cognition in healthy people.

Noopept

Noopept’s human evidence rests essentially on one trial. In a 2009 Russian study of people with mild cognitive disorders of vascular or traumatic origin, 31 received noopept and a comparison group received piracetam for 56 days. Both groups improved on several mood and cognitive measures.⁶⁵ The study was open-label, meaning participants and clinicians knew which drug was given, and it compared two active drugs. Without a blinded placebo comparison, improvements cannot be separated from expectation or natural recovery.

Head to head

That single open-label trial is also the only direct comparison. It is often cited as showing noopept “works better”, but an unblinded study of a few dozen patients cannot support that claim.

How they differ in practice, as reported

Because noopept is used at a tiny fraction of piracetam’s dose, products look very different: noopept is usually sold as small tablets or capsules, piracetam as large tablets or bulk powder. The Russian comparison trial used 10 mg of noopept twice daily against 400 mg of piracetam three times daily; these figures describe that study, not a recommendation.⁵

User reports online describe noopept as having a quicker, shorter-lived effect and piracetam as subtler. Some users report headaches with either and pair them with a choline source, a practice based on theory rather than trials. These accounts are anecdotal and uncontrolled.

Time course also differs on paper. Noopept itself is cleared within minutes in rodents, with effects attributed to its metabolite, while piracetam circulates as the active drug.⁵¹ How either translates into what users feel has not been studied in controlled human trials.

One practical difference matters more. Because noopept doses are so small, measurement errors in powders or poorly made capsules translate into large relative overdoses, a risk made concrete by US product testing.

Safety, side effects and interactions

Piracetam

Piracetam has a long clinical record and is generally described as well tolerated.¹ Its UK prescribing information lists nervousness, hyperkinesia and weight gain among the more frequent effects. It is contraindicated in cerebral haemorrhage, severe kidney impairment and Huntington’s chorea, and it reduces platelet aggregation, so caution is advised with bleeding risk, gastrointestinal ulcers or anticoagulant use. Stopping abruptly in people with myoclonus can trigger seizures.⁴

Noopept

In the only trial, reported side effects in the noopept group included sleep disturbances (5 of 31), irritability (3 of 31) and increased blood pressure (7 of 31). Drug interactions are unknown because there is so little clinical use outside Russia.⁵

Contents do not match labels

Researchers bought 10 US supplements labelled as containing omberacetam, aniracetam, phenylpiracetam or oxiracetam and analysed them with mass spectrometry. Several declared drugs were missing, and several undeclared ones were present. In that testing, omberacetam was found at up to 40.6 mg per serving, about four times a typical pharmacological dose, alongside undeclared unapproved drugs such as phenibut, vinpocetine and picamilon. Three in four declared quantities were inaccurate.¹⁰ A separate analysis found piracetam in four of five supplement brands tested, with daily intakes varying widely between products.⁹

Neither compound is on standard workplace drug panels. US service members should note that both appear on the Department of Defense Prohibited Dietary Supplement Ingredients List.¹¹

Legal status in September 2026

United States: neither is FDA-approved, and neither is a controlled substance. In a 2019 warning letter to a nootropics seller, the FDA stated that the company’s piracetam and noopept products, along with adrafinil and several other racetams, “are not dietary supplements or conventional foods”, making them unapproved new drugs when sold with health claims.⁸ The Department of Defense summarises the position as racetam drugs not being approved for use in the US as drugs or dietary supplement ingredients.¹¹ Enforcement has been limited, which is why these products remain easy to find.⁹

United Kingdom: piracetam is a prescription-only medicine, licensed as Nootropil for myoclonus of cortical origin in adults.⁴ Noopept has no UK marketing authorisation; selling it for its psychoactive effects may fall within the Psychoactive Substances Act 2016, which exempts licensed medicines but not unlicensed compounds.

European Union: piracetam is a nationally authorised medicine in more than 20 EU and EEA countries, including Germany, France, Italy and Spain, so it is supplied under national medicines rules rather than as a food.³ We found no EU authorisation for noopept.

Russia: noopept is available as a medicine and used clinically there.⁵

Canada: we found no piracetam or noopept product in Health Canada’s Drug Product Database, so neither is an authorised drug there.

What to check if you see these products for sale

• Supplement labelling is a red flag, not reassurance. In the US, a “dietary supplement” panel on piracetam or noopept is itself inconsistent with the FDA’s position.⁸
• “Research use only” wording on a product obviously meant to be swallowed shifts responsibility to you; see our explainer on what research use only means.
• Multi-ingredient “brain” blends can include undeclared drugs. A single-ingredient label is no proof of single-ingredient contents.¹⁰
• A certificate of analysis helps only if it is batch-specific, from an independent lab and tests for identity and quantity. It does not make an unapproved drug lawful or safe.
• Medical conditions matter. Anyone with kidney disease, a bleeding disorder, a history of stroke or seizures, or who takes anticoagulants should speak to a clinician before considering either.

Frequently asked questions

Is noopept stronger than piracetam?

Noopept is used at much lower milligram doses, which is where claims of it being “1,000 times stronger” come from. Potency by weight is not the same as a bigger effect. The only human comparison was a small open-label trial of the two drugs, which found improvements with both and cannot show that either is superior.⁶⁵

Is noopept a racetam?

Not strictly. Noopept was designed using piracetam’s structure and is often grouped with racetams, but chemically it is a dipeptide ester (N-phenylacetyl-L-prolylglycine ethyl ester). It appears to act largely through its metabolite cycloprolylglycine, whereas piracetam is active in its own right and in the comparison trial was given at a daily dose 60 times higher.⁵

Is piracetam legal in the US?

Piracetam is not a controlled substance, but it is not an FDA-approved drug and the FDA has told sellers that piracetam products are not dietary supplements. That means it cannot lawfully be marketed as a supplement or with health claims, even though enforcement has been limited and products remain available online.⁸⁹

Is piracetam prescription only in the UK?

Yes. In the UK piracetam is a prescription-only medicine, sold as Nootropil and licensed for adults with myoclonus of cortical origin, a movement disorder. It is not licensed for memory, focus or general cognitive enhancement, and supplying it without a prescription falls outside UK medicines law.⁴

What are the side effects of noopept?

Evidence is limited to one small trial and user reports. In that trial, some people taking noopept reported sleep disturbances, irritability and increased blood pressure. Because supplements have been found to contain up to four times a typical pharmacological dose, real-world exposure can be higher than intended.⁵¹⁰

Sources

1. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-182. DOI: 10.1111/j.1527-3458.2005.tb00268.x. PMID: 16007238. pubmed.ncbi.nlm.nih.gov
2. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011. DOI: 10.1002/14651858.CD001011. PMID: 11405971. pubmed.ncbi.nlm.nih.gov
3. European Medicines Agency. Piracetam: list of nationally authorised medicinal products (PSUSA/00002429/202204). EMA/382258/2015. 12 January 2023. ema.europa.eu
4. Mercury Pharmaceuticals (ADVANZ Pharma). Nootropil 800 mg film-coated tablets: summary of product characteristics. Legal category POM. Revised July 2025. Electronic Medicines Compendium. medicines.org.uk
5. Alzheimer’s Drug Discovery Foundation. Noopept. Cognitive Vitality report for researchers (PDF dated 2020). alzdiscovery.org
6. Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009;39(3):311-321. DOI: 10.1007/s11055-009-9128-4. PMID: 19234797. pubmed.ncbi.nlm.nih.gov
7. Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-337. DOI: 10.1007/s10517-008-0297-x. PMID: 19240853. pubmed.ncbi.nlm.nih.gov
8. US Food and Drug Administration. Warning letter to Peak Nootropics LLC aka Advanced Nootropics, MARCS-CMS 557887. 4 February 2019. fda.gov
9. Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Intern Med. 2020;180(3):458-459. DOI: 10.1001/jamainternmed.2019.5507. PMID: 31764936. pubmed.ncbi.nlm.nih.gov
10. Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I. Five unapproved drugs found in cognitive enhancement supplements. Neurol Clin Pract. 2021;11(3):e303-e307. DOI: 10.1212/CPJ.0000000000000960. PMID: 34484905. pubmed.ncbi.nlm.nih.gov
11. Operation Supplement Safety, US Department of Defense. Nootropics: drugs vs dietary supplements for brain health. Updated 12 May 2023. opss.org
12. Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012;(9):CD000419. DOI: 10.1002/14651858.CD000419.pub3. PMID: 22972044. pubmed.ncbi.nlm.nih.gov

Editorial note: This article is for general information only and is not medical or legal advice. Neither noopept nor piracetam is approved by the FDA, and the FDA has told sellers that products containing them are not dietary supplements. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.